Jetstream旋切联合Ranger药物涂层球囊治疗钙化股腘动脉病变无栓塞保护装置12个月结果
Ellipse多中心前瞻性观察研究纳入58例钙化TASC B/C股腘动脉病变患者,采用Jetstream旋切+Ranger药物涂层球囊、不使用栓塞保护装置。技术成功93%,无术后栓塞事件,12个月免于靶病变血运重建率为96%±3%。
要点
- 钙化TASC B/C股腘病变采用旋切联合药物涂层球囊,技术成功率达93%。
- 不使用栓塞保护装置时未观察到术后栓塞事件。
- 12个月免于靶病变血运重建率为96%±3%。
核心结论
- 旋切联合药物涂层球囊治疗复杂钙化股腘病变安全有效,技术成功率高、无术后栓塞事件,12个月免于TLR满意。
研究设计与样本
- 多中心前瞻性观察研究,2020年3月至2021年12月8个中心连续纳入58例钙化TASC B/C股浅动脉和/或膝上腘动脉病变患者。
- 排除支架内再狭窄和近期(<1个月)闭塞,所有患者均为致残性间歇性跛行(Rutherford 2和3级)。
主要发现
- 58例中2例靶病变置入支架、2例病变未能通过,54例完成全程操作,技术成功93%(54/58)。
- 术后病程均平稳,未观察到栓塞事件。
- 2例分别于3个月和9个月发生靶病变再狭窄,均接受普通球囊血管成形术治疗。
- Kaplan-Meier 12个月免于TLR为96%±3%(95%CI 0.9-1)。
关键数值与推荐
- 技术成功定义为完成旋切+药物涂层球囊全程操作,为93%(54/58)。
- 12个月免于TLR为96%±3%(95%CI 0.9-1)。
- 12个月一期通畅率94%±4%,二期通畅率98%±2%。
临床怎么用
- 对钙化TASC B/C股腘病变可采用Jetstream旋切后Ranger药物涂层球囊扩张的两步策略。
- 在排除高远端栓塞风险病变的选定患者中,可能无需使用栓塞保护装置。
局限性
- 为前瞻性观察研究,非随机对照,样本量58例且5例失访。
- 仅纳入Rutherford 2和3级、TASC B/C钙化病变,排除支架内再狭窄和近期闭塞,外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Endovascular treatment of complex femoro-popliteal lesions using plain angioplasty balloon and bare stents carries a high incidence of in-stent restenosis. Debulking using atherectomy device followed by angioplasty with drug coated balloon (DCB) has been proposed as an alternative option. However, few reports have published midterm outcomes and were focused on large inclusion criteria. The aim of this multicenter study was to report 12-month freedom from target lesion revascularization (TLR) following treatment of Trans-Atlantic Inter-Society Consensus (TASC) B and C femoro-popliteal lesions using JetStream® rotational plus aspiration atherectomy device and Ranger® DCB (Boston Scientific, Marlborough, MA, USA). METHODS: Between March 2020 and December 2021, consecutive patients from 8 centers, with de novo and calcified TASC B and C lesions of superficial femoral artery and/or above-knee popliteal arteries were included. Intra-stent restenosis and recent (<1 month) occlusions were excluded. All patients had disabling intermittent claudication (Rutherford class 2 and 3). Procedure was 2 steps: atherectomy using Jetstream and postdilatation using drug-coated Ranger balloon. No embolic protection device was used. Patients who had target lesion stenting were excluded. RESULTS: Fifty-eight patients signed informed consent and underwent the procedure. Two patients underwent stenting of the target lesion. Two had failure to cross the lesion. Fifty-four patients had the full procedure [technical success 93% (54/58)]. Postoperative course was uneventful in all patients, and no embolic event was observed. During follow-up, 2 patients died, and 5 were lost to follow-up. Forty-seven patients had complete 12 months clinical and duplex follow-up. Two patients had target lesion restenosis, respectively, at 3 and 9 months, which were treated by balloon angioplasty. Kaplan-Meier 12-month freedom from TLR was 96% ± 3% (95% confidence interval 0.9-1). CONCLUSION: Treatment of complex femoro-popliteal lesions using rotational atherectomy and DCB without embolic protection is safe and effective with high technical success rate, no postoperative embolic events, and satisfactory 12-month freedom from TLR.Clinical ImpactThe Ellipse study was a multicenter prospective observational trial on the treatment of calcified TASC B and C lesions using Jetstream atherectomy and Ranger drug-coated balloon with no embolic protection. This technique resulted in 93% technical success and no distal embolization. Twelve-month freedom from target lesion revascularization, primary and secondary patency were, respectively, 96% ± 3%, 94% ± 4%, and 98% ± 2%. Rotational atherectomy plus drug coated balloon is a safe and effective treatment of complex calcified femoro-popliteal lesions. Embolic protection might not be necessary in selected patients, when lesions at high risk of distal embolization are excluded.
引用
- Valerio N, Albertin J, Louis N, et al. Treatment of Calcified Femoro-Popliteal Lesions Using Jetstream® Atherectomy Device and Ranger® Drug-Coated Balloon Without Embolic Protection Device: 12-Month Results of the Ellipse Multicenter Study. J Endovasc Ther. 2025. PMID: 40650344. doi:10.1177/15266028251352788
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。